1,3-二氢-N，3,3-三甲基-1-苯基苯并[c]噻吩-1-丙胺盐酸盐 | 25487-28-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1,3-二氢-N，3,3-三甲基-1-苯基苯并[c]噻吩-1-丙胺盐酸盐
• 英文名称: Talsupram (hydrochloride)
• 英文别名: 3-(3,3-dimethyl-1-phenyl-2-benzothiophen-1-yl)-N-methylpropan-1-amine;hydrochloride
• CAS: 25487-28-9
• 化学式: C20H26ClNS
• 分子量: 347.9
• InChiKey: YMZCMCDSCRSIBS-UHFFFAOYSA-N

物化性质

• 溶解度：
  在水中溶解度为 20 mM，在 DMSO 中溶解度为 100 mM

计算性质

• 辛醇/水分配系数(LogP)：
  0.89
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  41.9
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Serotonin transport inhibitors
  申请人：——

  公开号：US20030105096A1

  公开（公告）日：2003-06-05

  The present invention relates to the therapeutic use of non-amine tropane analogues that bind to the SERT to treat neuropsychiatric disorders.

  本发明涉及治疗非胺类曲梯巴酮类似物与SERT结合以治疗神经精神障碍的用途。
• New drug combinations
  申请人：——

  公开号：US20020010216A1

  公开（公告）日：2002-01-24

  A composition comprising: (a) a pharmaceutically effective amount of one or more norepinephrine reuptake inhibitors or a pharmaceutically effective salt thereof, and (b) a pharmaceutically effective amount of one or more antimuscarinic agents or a pharmaceutically effective salt thereof is provided. The composition is useful in treating disorders or diseases of the central nervous system, and particularly useful in treating incontinence.

  一种组合物，包括 (a) 一种或多种去甲肾上腺素再摄取抑制剂或其药理有效量的盐，以及 (b) 一种或多种抗毒蕈碱药剂或其有效药用盐。该组合物可用于治疗中枢神经系统紊乱或疾病，特别是治疗尿失禁。
• NEW DRUG COMBINATIONS COMPRISING A NOREPINEPHRINE REUPTAKE INHIBITOR AND AN ANTIMUSCARINIC AGENT
  申请人：Pharmacia & Upjohn Company LLC

  公开号：EP1257277B1

  公开（公告）日：2005-06-15
• TREATMENT OF OBESITY-RELATED CONDITIONS
  申请人：Instituto de Medicina Molecular João Lobo Antunes

  公开号：EP3692042A1

  公开（公告）日：2020-08-12
• Treatment of Obesity-related Conditions
  申请人：INSTITUTO DE MEDICINA MOLECULAR

  公开号：US20200323797A1

  公开（公告）日：2020-10-15

  This invention relates to the finding that the inhibition of solute carrier family 6 member 2 (Slc6a2) exert a sympathomimetic effect outside the brain that promotes weight loss without concomitant hypophagia or hyperkinesia. Compounds for the inhibition of Slc6a2 outside the brain, as well as methods of promoting weight loss and treating obesity using such compounds are provided. TABLE 1